A5021210920- CAR-T cell therapy research
- Cutaneous lymphoproliferative disorders research
- Immunotherapy and Immune Responses
- Viral Infectious Diseases and Gene Expression in Insects
- Immune Cell Function and Interaction
- Virus-based gene therapy research
- Extracellular vesicles in disease
- Toxin Mechanisms and Immunotoxins
- Cytokine Signaling Pathways and Interactions
- Fungal Infections and Studies
- Biosimilars and Bioanalytical Methods
- interferon and immune responses
- Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- Blood groups and transfusion
- HIV/AIDS oral health manifestations
- Inflammatory Biomarkers in Disease Prognosis
- CRISPR and Genetic Engineering
- Venous Thromboembolism Diagnosis and Management
- Pediatric health and respiratory diseases
- RNA Interference and Gene Delivery
- Histiocytic Disorders and Treatments
- Immunodeficiency and Autoimmune Disorders
- Systemic Lupus Erythematosus Research
Inserm
2015-2024
Université de franche-comté
2006-2024
Université Bourgogne Franche-Comté
2014-2023
Établissement Français du Sang
2011-2021
Université de Bourgogne
2014-2016
Laboratoire de Biophotonique et Pharmacologie
2002
Centre International de Recherche sur le Cancer
1993
Centre National de la Recherche Scientifique
1993
The diagnosis of plasmacytoid dendritic cell leukaemia (pDCL) is based on the immunophenotypic profile: CD4(+) CD56(+) lineage(neg) CD45RA(+)/RO(neg) CD11c(neg) CD116(low) CD123(+) CD34(neg) CD36(+) HLA-DR(+). Several studies have reported pDCL cases that do not express this exact profile or expressing some lineage antigens could thus be misdiagnosed. This study aimed to validate pDCL-specific markers for by flow-cytometry quantitative reverse transcription polymerase chain reaction bone...
Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia for which we developed nationwide network to collect data from new cases diagnosed in France. In retrospective, observational study of 86 patients (2000-2013), described clinical biological focusing on morphologies immunophenotype. We found expression markers associated with origin (HLA-DRhigh, CD303+, CD304+, cTCL1+) plus CD4 CD56 frequent isolated the myeloid, B-, T-lymphoid lineages, whereas...
Abstract Chronic myeloid leukemia (CML) is a chronic disease resulting in cell expansion through expression of the BCR-ABL1 fusion transcript. Tyrosine kinase inhibitors (TKI) have significantly increased survival patients with CML, and deep responders may consider stopping treatment. However, more than 50% relapse restart TKI, subsequently suffering unknown toxicity. Because CML model immune system–sensitive disease, we hypothesize that chimeric antigen receptor (CAR) T cells targeting IL1...
Neoplasms involving plasmacytoid dendritic cells (pDC) include blastic pDC neoplasms (BPDCN) and other proliferations, where are associated with myeloid malignancies: most frequently chronic myelomonocytic leukemia (CMML) but also acute (AML), hereafter named pDC-AML. We aimed to determine the reactive or neoplastic origin of in pDC-AML, their link CD34+ blasts, monocytes conventional DC (cDC) same sample, by phenotypic molecular analyses (targeted next-generation sequencing, 70 genes)....
Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive leukemia of cells (pDC). BPDCN occurs at least three times more frequently in men than women, but the reasons for this sex bias are unknown. Here, studying genomics primary and modeling disease-associated mutations, we link acquired alterations RNA splicing to abnormal pDC development inflammatory response through Toll-like receptors. Loss-of-function mutations ZRSR2, X chromosome gene encoding a factor, enriched...
Abstract Oncogenesis and ontogeny of blastic plasmacytoid dendritic cell neoplasm (BPDCN) remain uncertain, between canonical cells (pDCs) AXL+ SIGLEC6+ DCs (AS-DCs). We compared 12 BPDCN to 164 acute leukemia by Affymetrix HG-U133 Plus 2.0 arrays: were closer B-cell lymphoblastic (ALL), with enrichment in pDC, signatures, vesicular transport, deubiquitination pathways, AS-DC but only some cases. Importantly, 1 T-cell ALL clustered BPDCN, compatible morphology, immunophenotype (cCD3+ sCD3−...
Background Acute myeloid leukemia (AML) remains a very difficult disease to cure due the persistence of leukemic stem cells (LSCs), which are resistant different lines chemotherapy and basis refractory/relapsed (R/R) in 80% patients with AML not receiving allogeneic transplantation. Methods In this study, we showed that interleukin-1 receptor accessory protein (IL-1RAP) is overexpressed on cell surface LSCs all subtypes confirmed it as an interesting promising target compared most common...
Background Increased circulating endothelial microparticles, resulting from vascular endothelium dysfunction, and plasmacytoid dendritic cell activation are both encountered in common inflammatory disorders. The aim of our study was to determine whether interactions between microparticles cells could contribute such pathologies.Design Methods Microparticles generated lines, platelets or activated T were incubated with human sorted healthy donor blood monocyte-derived cells. Dendritic...
Blastic plasmacytoid dendritic cell neoplasm is an aggressive malignancy derived from cells. There currently no accepted standard of care for treating this neoplasm, and therapeutic strategies have never been prospectively evaluated. Since blastic cells express high levels interleukin-3 receptor α chain (IL3-Rα or CD123), antitumor effects the receptor-targeted drug SL-401 against were evaluated in vitro vivo. The cytotoxicity was assessed patient-derived lines (CAL-1 GEN2.2) primary...
Blastic plasmacytoid dendritic cell neoplasm is an aggressive hematologic malignancy with a poor prognosis. No consensus regarding optimal treatment modalities currently available. Targeting the nuclear factor-kappa B pathway considered promising approach since blastic has been reported to exhibit constitutive activation of this pathway. Moreover, inhibition in lines, achieved using either experimental specific inhibitor JSH23 or clinical drug bortezomib, interferes vitro leukemic...
Abstract Extracellular vesicles (EVs) are active components of red blood cell (RBC) concentrates and may be associated with beneficial adverse effects transfusion. Elucidating controllable factors EV release in RBC products is thus important to better manage the quality properties units. Erythrocyte-derived EVs (EEVs) platelet-derived (PEVs) were counted 1226 units (administered 280 patients) using a standardized cytometry-based method. size CD47 annexin V expression also measured. The donor...
Chimeric Antigen Receptor (CAR) therapy has led to great successes in patients with leukemia and lymphoma. Umbilical Cord Blood (UCB), stored UCB banks, is an attractive source of T cells for CAR-T production. We used a third generation CD123 (CD28/4-1BB), which was previously developed using adult's Peripheral (PB), test the ability obtaining from fresh or cryopreserved UCB. obtained cell product high stable transduction efficacy, poorly differentiated phenotype cells, while retaining...
Abstract Diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN) or leukemia (pDCL) is mainly based on immunophenotypical characterization leukemic cells in blood bone marrow samples. We tested by flow cytometry intracellular expression the proto‐oncogene T‐cell 1 (TCL1), as well membrane and immunoglobulin‐like transcript 7 (ILT7) 21 pDCL samples 61 non‐pDC acute [i.e., 14 B‐acute lymphoblastic (B‐ALL), 9 T‐ALL 38 myeloid (AML)]. TCL1 highly expressed all while at a statistically...
Purpose: Microparticles (MPs) are membrane-derived vesicles measuring less than 1 μm in diameter. They shed from nearly every activated or preapoptotic cell and may exhibit biologic activities inflammation apoptosis settings. The main purpose of this study was to determine whether MP shedding higher the vitreous patients with retinal detachment (RD). Methods: This a prospective, comparative study. Levels MPs (including phosphatidylserine [PS]-expressing MPs, photoreceptor cell–derived...
BACKGROUND The procoagulant and proinflammatory microparticles (MPs) released during storage of packed red blood cells (pRBCs) can potentially modify transfusion benefits. A robust method to quantify MPs in pRBCs is needed evaluate their impact clinical trials. STUDY DESIGN AND METHODS objective was validate the preanalytic conditions required prepare pRBC supernatant as well a MP variations over 42 days storage.A flow cytometry with size‐calibrated beads developed fully validated....
Mucous peristalsis, mucus and immunity proteins, such as lysozyme lactoferrin, are part of humoral innate immunity. The aim this study was to develop a quantitative method, time-resolved-immunofluorometric assay, measure lactoferrin in sera, saliva, stools cervico-vaginal secretions. This method validated 51 healthy subjects. Linearity for between 1.02 25 μg/l 100 μg/. detection limit 0.5 1 lactoferrin. Albumin α1-antitrypsin were measured by immuno-nephelometry calculate salivary,...